Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance

20 Jun 2019

Abstract excerpt

Conventional HIV drug resistance (HIVDR) genotyping utilizes Sanger sequencing (SS) methods, which are limited by low data throughput and the inability of detecting low abundant drug resistant variants (LADRVs). Here we present a next generation sequencing (NGS)-based HIVDR typing platform that leverages the advantages of Illumina MiSeq and HyDRA Web. The platform consists of a fully validated sample processing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Pneumocystis jirovecii pneumonia detection and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31222149
DOI: 10.1038/s41598-019-45328-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillancePMID 31222149Read ↗

Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing.Semantic proximity Read ↗

Validation of publicly-available software used in analyzing NGS data for HIV-1 drug resistance mutations and transmission networks in a Washington, DC, CohortSemantic proximity Read ↗

Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.Semantic proximity Read ↗

HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance PipelineSemantic proximity Read ↗

HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance PipelineSemantic proximity Read ↗

HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies.Semantic proximity Read ↗

Deep sequencing for HIV-1 clinical management.Semantic proximity Read ↗

G-HIV: An Integrated Long-Read Sequencing and Automated Bioinformatics Platform for Rapid and Precise HIV-1 SurveillanceSemantic proximity Read ↗

Technologies for HIV-1 drug resistance testing: inventory and needs.Semantic proximity Read ↗

Validation of a HIV Whole Genome Sequencing Method for HIV Drug Resistance Testing in an Australian Clinical Microbiology LaboratorySemantic proximity Read ↗

Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” SymposiumSemantic proximity Read ↗

Validation of an HIV whole genome sequencing method for HIV drug resistance testing in an Australian clinical microbiology laboratory.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.